Novavax (NASDAQ: NVAX) reviewed 10-14-2020
Market Cap: $7.23 Billion (USD) Share Price: $118.00 (USD)
Shares outstanding: 61,262,632 as of 30 Jun 2020
Cash & cash equivalents: $424,395 M (USD) as of 30 Jun 2020
Debt: $323,321 M (USD) via Convertible notes
Insiders: Low Institutional: 36 holders own approx. 14%
Website: novavax.com
Investor Presentations: https://novavax.com/resources#presentations
CEO: Stanley C. Erck HQs: Gaithersburg, MD, USA
Novavax is a phase 2 & 3-stage biotech with vaccines to prevent infectious RSV disease in infants and seasonal flu in adults as well as some of the world’s toughest viruses
The vaccine technology combines genetic engineering with the immunogenicity enhancing properties of the company’s proprietary Matrix-M adjuvant
R&D pipeline includes vaccines in various phases of development to address these viruses:
- NVX-CoV2373 – Coronavirus – Phase 1
- Nanoflu – Influenza – Phase 3
- Resvax-RSV F Vaccine (Infants) – Respiratory Syncytial Virus (RSV) – Phase 3
- RSV F Vaccine (adults) – Phase 2
- RSV-F Vaccine (Pediatrics) – Phase 1
- Ebola GP Vaccine – Phase 1
- MERS – Pre-clinical phase
- SARS – Pre-clinical phase
- Seasonal flu (Age: 60+) – Pre-clinical phase
Bottom line:
- As an mRNA alternative, their DNA approach might become an industry leader